Search

Search Constraints

You searched for: Author/Creator Whittaker, Sean

Search Results

2. A case of cutaneous peripheral T-cell not otherwise specified (PTCL-NOS), successfully treated with brentuximab vedotin after disease progression on standard chemotherapy. (October 2021)

3. Aggressive epidermotropic cutaneous CD8+ lymphoma: a cutaneous lymphoma with distinct clinical and pathological features. Report of an EORTC Cutaneous Lymphoma Task Force Workshop. Issue 4 (24th February 2015)

4. Brentuximab vedotin (BV) versus physician's choice (PC) of methotrexate or bexarotene in adult patients with previously treated CD30-positive cutaneous T-cell lymphoma (CTCL; mycosis fungoides [MF] or primary cutaneous anaplastic large cell lymphoma [pcALCL]): final time to next therapy (TTNT) results from the phase 3 ALCANZA study. (2019)

5. Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Issue 10094 (5th August 2017)

6. CD56-positive haematological neoplasms of the skin: a multicentre study of the Cutaneous Lymphoma Project Group of the European Organisation for Research and Treatment of Cancer. Issue 9 (3rd October 2006)

7. Characterization and outcomes in patients with mogamulizumab-associated skin reactions in the MAVORIC trial. (October 2021)

8. Clinical, histopathological and prognostic features of primary cutaneous acral CD8+ T‐cell lymphoma and other dermal CD8+ cutaneous lymphoproliferations: results of an EORTC Cutaneous Lymphoma Group workshop. (2nd May 2022)

9. Clinical, histopathological and prognostic features of primary cutaneous acral CD8+ T‐cell lymphoma and other dermal CD8+ cutaneous lymphoproliferations: results of an EORTC Cutaneous Lymphoma Group workshop. (1st May 2022)

10. Clinically significant responses achieved with romidepsin across disease compartments in patients with cutaneous T-cell lymphoma. Issue 10 (3rd October 2015)